Wellbrock, Jasmin
Behrmann, Lena
Muschhammer, Jana
Modemann, Franziska
Khoury, Kais
Brauneck, Franziska
Bokemeyer, Carsten
Campeau, Eric
Fiedler, Walter
Funding for this research was provided by:
This research was funded by the Eppendorfer Krebs- und Leukämiehilfe e.V.
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 14 April 2021
Accepted: 7 July 2021
First Online: 1 August 2021
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Ethik-Kommission der Ärztekammer Hamburg (code PV3469, date of approval: 06–17-2010).
: Informed consent was obtained from all subjects involved in the study.
: All authors have read and agreed to the published version of the manuscript.
: E.C. is a full-time employee of Zenith Epigenetics Ltd.; F.M. received support for meeting attendance from Servier, Incyte, Gilead, Jazz Pharmaceuticals, Novartis, Teva, Pfizer, Amgen, received research grant from Daiichi Sankyo and received speaker honorarium from Servier; F.B. received travel grants from Daiichi Sankyo, Servier, Novartis; advisory board Jazz. GmbH, Daiichi Sankyo, Servier; C.B. reports personal fees from Sanofi Aventis, Merck KgA, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly Imclone, Bayer Healthcare, GSO Contract Research, AOK Rheinland-Hamburg, Novartis, outside the submitted work; W.F. reports membership on an entity’s board of directors or advisory committee for AbbVie, Amgen, ARIAD/Incyte, Celgene, Jazz Pharmaceuticals, MorphoSys AG, Novartis, and Pfizer; patents and royalties from Amgen; support for meeting attendance Amgen, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals, and Servier; research funding from Amgen and Pfizer. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.